Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 99

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Systematic Review and Meta-Analysis of the Epidemiology of Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Isolates

Zhang, Shanshan, Sun, Xiaoxi, Chang, Wenjiao, Dai, Yuanyuan, Ma, Xiaoling·2015·PLOS ONE

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0136082

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 121

  1. FD Lowy, 1998, Staphylococcus aureus infections, The New England journal of medicine, 339, 520, 10.1056/NEJM199808203390806 · DOI · Paper page
  2. CL M, 2007, Community-associated methicillin-resistant Staphylococcus aureus isolates causing healthcare-associated infections, Emerg Infect Dis, 13, 236, 10.3201/eid1302.060781 · DOI · Paper page
  3. M LC, 2006, Trends in Antimicrobial Resistance in Health Care-Associated Pathogens and Effect on Treatment, Clinical Infectious Diseases, 42
  4. KS Kaye, 2004, Reference group choice and antibiotic resistance outcomes, Emerging infectious diseases, 10, 1125, 10.3201/eid1006.020665 · DOI
  5. K. H, 2001, Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance, The Lancet Infectious Diseases, 1, 147, 10.1016/S1473-3099(01)00091-3 · DOI · Paper page
  6. SK Fridkin, 2001, Vancomycin-intermediate and -resistant Staphylococcus aureus: what the infectious disease specialist needs to know, Clin Infect Dis, 32, 108, 10.1086/317542 · DOI · Paper page
  7. K H, 1998, The emergence of Staphylococcus aureus with reduced susceptibility to vancomycin in Japan, The American Journal of Medicine, 5A, 7S
  8. MJ R, 2001, Emergence of methicillin-resistant Staphylococcus aureus with intermediate glycopeptide resistance: clinical significance and treatment options, Drugs, volume 61, 1, 10.2165/00003495-200161010-00001 · DOI
  9. SJv Hal, 2011, Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates, Antimicrob Agents Chemother, 55, 405, 10.1128/AAC.01133-10 · DOI · Paper page
  10. J Ariza, 1999, Vancomycin in surgical infections due to methicillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin, Lancet, 353, 1587, 10.1016/S0140-6736(99)01017-X · DOI · Paper page
  11. MN Kim, 2000, Vancomycin-intermediate Staphylococcus aureus in Korea, Journal of clinical microbiology, 38, 3879, 10.1128/JCM.38.10.3879-3881.2000 · DOI
  12. LH Sng, 2005, Heterogeneous vancomycin-resistant Staphylococcus aureus (hetero-VISA) in Singapore, International journal of antimicrobial agents, 25, 177, 10.1016/j.ijantimicag.2004.11.001 · DOI
  13. C Liu, 2003, Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods, Antimicrob Agents Chemother, 47, 3040, 10.1128/AAC.47.10.3040-3045.2003 · DOI · Paper page
  14. N Mantel, 1959, Statistical aspects of the analysis of data from retrospective studies of disease, Journal of the National Cancer Institute, 15, 639
  15. R Dersimonian, 1986, N: Meta-analysis in clinical trials, Controlled Clinical Trials
  16. JP Higgins, 2002, Quantifying heterogeneity in a meta-analysis, Stat Med, 21, 1539, 10.1002/sim.1186 · DOI · Paper page
  17. MF Freeman, 1950, Transformations Related to the Angular and the Square Root, ANNALS OF MATHEMATICAL STATISTICS, 6, 180
  18. F Garnier, 2006, A 1 year surveillance study of glycopeptide-intermediate Staphylococcus aureus strains in a French hospital, The Journal of antimicrobial chemotherapy, 57, 146, 10.1093/jac/dki413 · DOI
  19. H Hanaki, 2014, Antibiotic susceptibility survey of blood-borne MRSA isolates in Japan from 2008 through 2011, Journal of infection and chemotherapy: official journal of the Japan Society of Chemotherapy, 20, 527, 10.1016/j.jiac.2014.06.012 · DOI
  20. SS W, 1999, Bacteremia caused by staphylococci with inducible vancomycin heteroresistance, Clinical Infectious Diseases, 29, 760, 10.1086/520429 · DOI · Paper page
  21. MJ Rybak, 2008, Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007), Journal of clinical microbiology, 46, 2950, 10.1128/JCM.00582-08 · DOI
  22. M Pastagia, 2009, Clinical and bacteriologic characteristics of a 5-year cohort of MRSA patients at a large U.S. metropolitan hospital, Clinical Microbiology and Infection, 15, S20
  23. RK Fong, 2009, Clinical features and treatment outcomes of vancomycin-intermediate Staphylococcus aureus (VISA) and heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA) in a tertiary care institution in Singapore, European journal of clinical microbiology & infectious diseases: official publication of the European Society of Clinical Microbiology, 28, 983, 10.1007/s10096-009-0741-5 · doi:10.1007/s10096-009-0741-5
  24. PG C, 2004, Clinical Features Associated with Bacteremia Due to Heterogeneous Vancomycin-Intermediate Staphylococcus aureus, Clinical Infectious Diseases, 38, 448, 10.1086/381093 · DOI · Paper page
  25. Y Maor, 2009, Clinical features of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia, The Journal of infectious diseases, 199, 619, 10.1086/596629 · DOI · Paper page
  26. PR Hsueh, 2010, Clonal dissemination of meticillin-resistant and vancomycin-intermediate Staphylococcus aureus in a Taiwanese hospital, International journal of antimicrobial agents, 36, 307, 10.1016/j.ijantimicag.2010.06.035 · DOI
  27. MN Kim, 2002, Clonal Spread of Staphylococcus aureus Heterogeneously Resistant to Vancomycin in a University Hospital in Korea, Journal of clinical microbiology, 40, 1376, 10.1128/JCM.40.4.1376-1380.2002 · DOI
  28. KH Park, 2012, Comparison of the clinical features, bacterial genotypes and outcomes of patients with bacteraemia due to heteroresistant vancomycin-intermediate Staphylococcus aureus and vancomycin-susceptible S. aureus, The Journal of antimicrobial chemotherapy, 67, 1843, 10.1093/jac/dks131 · DOI
  29. C Hafer, 2012, Contribution of selected gene mutations to resistance in clinical isolates of vancomycin-intermediate Staphylococcus aureus, Antimicrobial agents and chemotherapy, 56, 5845, 10.1128/AAC.01139-12 · DOI
  30. A dL, 2006, Control And Outcome Of A Large Outbreak Of Colonization And Infection With Glycopeptide-Intermediate Staphylococcus Aureus In An Intensive Care Unit, Clinical Infectious Diseases, 42, 170, 10.1086/498898 · DOI
  31. F Kaleem, 2012, Current status of Glycopeptide intermediate and heterogenous Glycopeptide intermediate Staphylococcus aureus and their prevailing susceptibility pattern at two tertiary care hospitals of Pakistan, International Journal of Infectious Diseases, 16, e420, 10.1016/j.ijid.2012.05.582 · doi:10.1016/j.ijid.2012.05.582
  32. J Robert, 2006, Decreased susceptibility to glycopeptides in methicillin-resistant Staphylococcus aureus: a 20 year study in a large French teaching hospital, 1983–2002, The Journal of antimicrobial chemotherapy, 57, 506, 10.1093/jac/dki486 · DOI
  33. HJ Adam, 2010, Detection and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates in Canada: results from the Canadian Nosocomial Infection Surveillance Program, 1995–2006, Antimicrobial agents and chemotherapy, 54, 945, 10.1128/AAC.01316-09 · DOI
  34. T Takata, 2009, Detection of Heterogeneous Vancomycin Intermediate Staphylococcus aureus (hetero-VISA) in MRSA of Japanese Clinical Isolates, American Journal of Infection Control, 37, E15, 10.1016/j.ajic.2009.04.011 · doi:10.1016/j.ajic.2009.04.011
  35. SS Richter, 2011, Detection of Staphylococcus aureus isolates with heterogeneous intermediate-level resistance to vancomycin in the United States, Journal of clinical microbiology, 49, 4203, 10.1128/JCM.01152-11 · DOI
  36. K Hiramatsu, 1997, Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin, The Lancet, 350, 1670, 10.1016/S0140-6736(97)07324-8 · DOI · Paper page
  37. SJ Van Hal, 2011, Emergence and evolution of heteroresistant vancomycin intermediate Staphylococcus aureus in a single hospital over a 12-year period, Clinical Microbiology and Infection, 17, S58
  38. JH Song, 2004, Emergence in Asian countries of Staphylococcus aureus with reduced susceptibility to vancomycin, Antimicrobial agents and chemotherapy, 48, 4926, 10.1128/AAC.48.12.4926-4928.2004 · DOI
  39. R Geisel, 1999, Emergence of heterogeneous intermediate vancomycin resistance in Staphylococcus aureus isolates in the Dusseldorf area, The Journal of antimicrobial chemotherapy, 43, 846, 10.1093/jac/43.6.846 · DOI · Paper page
  40. S Gowrishankar, 2013, Emergence of methicillin-resistant, vancomycin-intermediate Staphylococcus aureus among patients associated with group A Streptococcal pharyngitis infection in southern India, Infection, genetics and evolution: journal of molecular epidemiology and evolutionary genetics in infectious diseases, 14, 383, 10.1016/j.meegid.2013.01.002 · doi:10.1016/j.meegid.2013.01.002
  41. O Denis, 2002, Emergence of vancomycin-intermediate Staphylococcus aureus in a Belgian hospital: microbiological and clinical features, Journal of Antimicrobial Chemotherapy, 50, 383, 10.1093/jac/dkf142 · DOI
  42. T Lewis, 2009, Epidemiology of MRSA bacteraemia and clinical relevance of reduced susceptibility to vancomycin, Clinical Microbiology and Infection, 15, S544
  43. AM Casapao, 2014, Evaluation of vancomycin population susceptibility analysis profile as a predictor of outcomes for patients with infective endocarditis due to methicillin-resistant Staphylococcus aureus, Antimicrobial agents and chemotherapy, 58, 4636, 10.1128/AAC.02820-13 · DOI
  44. S Trakulsomboon, 2001, First report of methicillin-resistant Staphylococcus aureus with reduced susceptibility to vancomycin in Thailand, Journal of clinical microbiology, 39, 591, 10.1128/JCM.39.2.591-595.2001 · DOI
  45. A Lulitanond, 2009, The first vancomycin-intermediate Staphylococcus aureus strains isolated from patients in Thailand, Journal of clinical microbiology, 47, 2311, 10.1128/JCM.01749-08 · DOI
  46. A K, 2004, Frequency of Reduced Vancomycin Susceptibility and Heterogeneous Subpopulation in Persistent or Recurrent Methicillin-Resistant Staphylococcus aureus Bacteremia, Clin Infect Dis, 38, 1328, 10.1086/383036 · DOI
  47. MD El Ayoubi, 2014, Glycopeptide intermediate Staphylococcus aureus and prevalence of the luk-PV gene in clinical isolates, in Northern Lebanon, Medecine et maladies infectieuses, 44, 223, 10.1016/j.medmal.2014.03.004 · DOI
  48. SK H, 1999, Glycopeptide-intermediate Staphylococcus aureus: evaluation of a novel screening method and results of a survey of selected U.S. hospitals, Journal of clinical microbiology, 3590
  49. A M, 2000, Heterogeneous vancomycin resistance in methicillin-resistant Staphylococcus aureus strains isolated in a large Italian hospital, Journal of clinical microbiology, 2, 866
  50. CN Chaudhari, 2015, Heterogeneous vancomycin-intermediate among methicillin resistant Staphylococcus aureus, Medical journal, Armed Forces India, 71, 15, 10.1016/j.mjafi.2014.03.008 · DOI
  51. F Campanile, 2010, Heteroresistance to glycopeptides in Italian meticillin-resistant Staphylococcus aureus (MRSA) isolates, International journal of antimicrobial agents, 36, 415, 10.1016/j.ijantimicag.2010.06.044 · DOI
  52. A Delgado, 2007, Hetero-vancomycin-intermediate methicillin-resistant Staphylococcus aureus isolate from a medical center in Las Cruces, New Mexico, Journal of clinical microbiology, 45, 1325, 10.1128/JCM.02437-06 · DOI
  53. I Uckay, 2012, High prevalence of isolates with reduced glycopeptide susceptibility in persistent or recurrent bloodstream infections due to methicillin-resistant Staphylococcus aureus, Antimicrobial agents and chemotherapy, 56, 1258, 10.1128/AAC.05808-11 · DOI
  54. JL Wang, 2013, High vancomycin minimum inhibitory concentrations with heteroresistant vancomycin-intermediate Staphylococcus aureus in meticillin-resistant S. aureus bacteraemia patients, International journal of antimicrobial agents, 42, 390, 10.1016/j.ijantimicag.2013.07.010 · DOI
  55. H-m Neoh, Impact of reduced vancomycin susceptibility on the therapeutic outcome of MRSA bloodstream infections, Annals of Clinical Microbiology and Antimicrobials, 6, 13
  56. K Kosowska-Shick, 2008, Incidence and characteristics of vancomycin nonsusceptible strains of methicillin-resistant Staphylococcus aureus at Hershey Medical Center, Antimicrobial agents and chemotherapy, 52, 4510, 10.1128/AAC.01073-08 · DOI
  57. H Chen, 2011, The incidence of heterogeneous vancomycin-intermediate Staphylococcus aureus correlated with increase of vancomycin MIC, Diagnostic microbiology and infectious disease, 71, 301, 10.1016/j.diagmicrobio.2011.06.010 · DOI
  58. ME Reverdy, 2001, Incidence of Staphylococcus aureus with reduced susceptibility to glycopeptides in two French hospitals, Clinical Microbiology and Infection: the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases, 7, 267, 10.1046/j.1198-743x.2001.00256.x · DOI
  59. MM Fitzgibbon, 2007, Investigation of reduced susceptibility to glycopeptides among methicillin-resistant Staphylococcus aureus isolates from patients in Ireland and evaluation of agar screening methods for detection of heterogeneously glycopeptide-intermediate S. aureus, Journal of clinical microbiology, 45, 3263, 10.1128/JCM.00836-07 · DOI
  60. Y Nakipoglu, 2005, Investigation of Staphylococcus strains with heterogeneous resistance to glycopeptides in a Turkish university hospital, BMC infectious diseases, 5, 31, 10.1186/1471-2334-5-31 · DOI
  61. AC Silveira, 2014, Is prediffusion test an alternative to improve accuracy in screening hVISA strains and to detect susceptibility to glycopeptides/lipopeptides?, Diagnostic microbiology and infectious disease, 79, 401, 10.1016/j.diagmicrobio.2014.04.008 · DOI
  62. JM E, 2005, Low colonization prevalence of Staphylococcus aureus with reduced vancomycin susceptibility among patients undergoing hemodialysis in the San Francisco Bay area, Clinical Infectious Diseases, 40, 1617, 10.1086/429906 · DOI
  63. SL Fink, 2012, Low prevalence of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates among Connecticut veterans, Antimicrobial agents and chemotherapy, 56, 582, 10.1128/AAC.05024-11 · DOI
  64. C N, 2005, Low prevalence of methicillin-resistant Staphylococcus aureus with reduced susceptibility to glycopeptides in Belgian hospitals, Clinical Microbiology and Infection, 11, 214, 10.1111/j.1469-0691.2004.01060.x · DOI
  65. GL C, 2004, Methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to glycopeptides (GISA) in 63 French general hospitals, Clinical Microbiology and Infection, 10, 448, 10.1111/j.1469-0691.2004.00830.x · DOI
  66. B Sancak, 2005, Methicillin-resistant Staphylococcus aureus heterogeneously resistant to vancomycin in a Turkish university hospital, The Journal of antimicrobial chemotherapy, 56, 519, 10.1093/jac/dki272 · DOI
  67. P Panomket, 2014, Methicillin-resistant Staphylococcus aureus with reduced susceptibility to vancomycin in Sanprasitthiprasong Hospital, Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 97, S7
  68. WY Wang, 2009, Molecular and phenotypic characteristics of methicillin-resistant and vancomycin-intermediate staphylococcus aureus isolates from patients with septic arthritis, Journal of clinical microbiology, 47, 3617, 10.1128/JCM.00539-09 · DOI
  69. C Liu, 2014, Molecular characteristics and virulence factors in methicillin-susceptible, resistant, and heterogeneous vancomycin-intermediate Staphylococcus aureus from central-southern China, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi
  70. SY Lin, 2012, Molecular epidemiology and clinical characteristics of hetero-resistant vancomycin intermediate Staphylococcus aureus bacteremia in a Taiwan Medical Center, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi, 45, 435, 10.1016/j.jmii.2012.05.004 · DOI
  71. HB Kim, 2003, Nationwide Surveillance for Staphylococcus aureus with Reduced Susceptibility to Vancomycin in Korea, Journal of clinical microbiology, 41, 2279, 10.1128/JCM.41.6.2279-2281.2003 · DOI
  72. G Chung, 2010, Nationwide surveillance study of vancomycin intermediate Staphylococcus aureus strains in Korean hospitals from 2001 to 2006, Journal of microbiology and biotechnology, 20, 637
  73. Y Ike, 2001, Nationwide survey shows that methicillin-resistant Staphylococcus aureus strains heterogeneously and intermediately resistant to vancomycin are not disseminated throughout Japanese hospitals, Journal of clinical microbiology, 39, 4445, 10.1128/JCM.39.12.4445-4451.2001 · DOI
  74. H Hanaki, 2007, Occurrence of vancomycin-intermediate-resistant Staphylococcus aureus in Japan, Journal of infection and chemotherapy: official journal of the Japan Society of Chemotherapy, 13, 118, 10.1007/s10156-006-0498-Z · DOI
  75. HS Sader, 2009, Occurrence of vancomycin-tolerant and heterogeneous vancomycin-intermediate strains (hVISA) among Staphylococcus aureus causing bloodstream infections in nine USA hospitals, The Journal of antimicrobial chemotherapy, 64, 1024, 10.1093/jac/dkp319 · DOI
  76. S Parer, 2012, An outbreak of heterogeneous glycopeptide-intermediate Staphylococcus aureus related to a device source in an intensive care unit, Infection control and hospital epidemiology, 33, 167, 10.1086/663703 · DOI
  77. A N, 2012, The presence of heterogeneous vancomycin-lntermediate Staphylococcus aureus (heteroVISA) in a major Malaysian hospital, The Medical journal of Malaysia
  78. G B, 1999, Presence of Staphylococcus aureus with Reduced Susceptibility to Vancomycin in Germany, European Journal of Clinical Microbiology and Infectious Diseases, 18, 691, 10.1007/s100960050380 · DOI
  79. CM Ho, 2010, Prevalence and accessory gene regulator (agr) analysis of vancomycin-intermediate Staphylococcus aureus among methicillin-resistant isolates in Taiwan—SMART program, 2003, European journal of clinical microbiology & infectious diseases: official publication of the European Society of Clinical Microbiology, 29, 383, 10.1007/s10096-009-0868-4 · DOI
  80. Y Maor, 2007, Prevalence and characteristics of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia in a tertiary care center, Journal of clinical microbiology, 45, 1511, 10.1128/JCM.01262-06 · DOI
  81. W Sun, 2009, Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China, Antimicrobial agents and chemotherapy, 53, 3642, 10.1128/AAC.00206-09 · DOI
  82. Y W, 2013, Prevalence and clinical prognosis of heteroresistant vancomycin-intermediate Staphylococcus aureus in a tertiary care center in China, Chin Med J (Engl), 126, 505, 10.3760/cma.j.issn.0366-6999.20120812 · doi:10.3760/cma.j.issn.0366-6999.20120812
  83. M Chaudhary, 2013, Prevalence of heterogeneous glycopeptide intermediate resistance in Methicillin-Resistant Staphylococcus aureus, American Journal of Infectious Diseases, 9, 63, 10.3844/ajidsp.2013.63.70 · DOI
  84. P Vaudaux, 2012, Prevalence of isolates with reduced glycopeptide susceptibility in orthopedic device-related infections due to methicillin-resistant Staphylococcus aureus, European journal of clinical microbiology & infectious diseases: official publication of the European Society of Clinical Microbiology, 31, 3367, 10.1007/s10096-012-1705-8 · DOI
  85. B Khanal, 2010, Prevalence of Vancomycin Intermediate Staphyloccus aureus (VISA) in a tertiary care hospital in Eastern Nepal, International Journal of Infectious Diseases, 14, e342, 10.1016/j.ijid.2010.02.381 · doi:10.1016/j.ijid.2010.02.381
  86. F Bert, 2003, Prevalence, Molecular Epidemiology, and Clinical Significance of Heterogeneous Glycopeptide-Intermediate Staphylococcus aureus in Liver Transplant Recipients, Journal of clinical microbiology, 41, 5147, 10.1128/JCM.41.11.5147-5152.2003 · DOI
  87. KC Horne, 2009, Prospective comparison of the clinical impacts of heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-susceptible MRSA, Antimicrobial agents and chemotherapy, 53, 3447, 10.1128/AAC.01365-08 · DOI
  88. R Canton, 1999, Prospective study of Staphylococcus aureus with reduced susceptibility to glycopeptides, Revista espanola de quimioterapia: publicacion oficial de la Sociedad Espanola de Quimioterapia, 12, 48
  89. M K, 1999, Reduced susceptibility to vancomycin of nosocomial isolates of methicillin-resistant Staphylococcus aureus, The Journal of antimicrobial chemotherapy, 43, 729, 10.1093/jac/43.5.729 · DOI
  90. R Khatib, 2011, Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia, The Journal of antimicrobial chemotherapy, 66, 1594, 10.1093/jac/dkr169 · DOI
  91. HA Bataineh, 2006, Resistance of Staphylococcus aureus to vancomycin in Zarqa, Jordan, Pakistan Journal of Medical Sciences, 22, 144
  92. SR Ramli, 2012, Screening and detection of heterogenous vancomycin intermediate Staphylococcus aureus in Hospital Kuala Lumpur Malaysia, using the glycopeptide resistance detection Etest and population analysis profiling, Infectious disease reports, 4, e20, 10.4081/idr.2012.3836 · doi:10.4081/idr.2012.3836
  93. D Pierard, 2004, Screening for Staphylococcus aureus with a reduced susceptibility to vancomycin in: a Belgian hospital, Pathologie-biologie, 52, 486, 10.1016/j.patbio.2004.07.016 · DOI
  94. A Mlynarczyk, 2003, Searching for Staphylococcus aureus strains with reduced susceptibility to glycopeptides among clinical isolates obtained during the year of 2002, Medycyna doswiadczalna i mikrobiologia, 55, 209
  95. D F, 1999, Seeking Vancomycin Resistant Staphylococcus aureus among Patients with Vancomycin-Resistant Enterococci, Clinical Infectious Diseases, 29, 1566, 10.1086/313530 · DOI
  96. A Kirby, 2010, Staphylococcus aureus with reduced glycopeptide susceptibility in Liverpool, UK, The Journal of antimicrobial chemotherapy, 65, 721, 10.1093/jac/dkq009 · doi:10.1093/jac/dkq009
  97. D Dubey, 2013, Surveillance of infection status of drug resistant Staphylococcus aureus in an Indian teaching hospital, Asian Pacific Journal of Tropical Disease, 3, 133, 10.1016/S2222-1808(13)60057-2 · DOI
  98. Y Guo, 2013, A surveillance study of antimicrobial resistance of gram-positive cocci strains isolated from 16 teaching hospitals in China in 2012, Chinese Journal of Microbiology and Immunology (China), 33, 401
  99. F-J Schmitz, 1999, Susceptibility of 302 methicillin-resistant Staphylococcus aureus isolates from 20 European university hospitals to vancomycin and alternative antistaphylococcal compounds, European Journal of Clinical Microbiology and Infectious Diseases, 18, 528, 10.1007/s100960050340 · doi:10.1007/s100960050340
  100. HM A, 2000, Twenty months of screening for glycopeptide-intermediate Staphylococcus aureus, The Journal of antimicrobial chemotherapy, 46, 639, 10.1093/jac/46.4.639-a · doi:10.1093/jac/46.4.639-a
  101. B S, 2013, Vancomycin and daptomycin minimum inhibitory concentration distribution and occurrence of heteroresistance among methicillin-resistant Staphylococcus aureus blood isolates in Turkey, BMC infectious diseases, 13, 46
  102. J Ariza, 1999, Vancomycin in surgical infections due to meticillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin, The Lancet, 353, 1587, 10.1016/S0140-6736(99)01017-X · DOI · Paper page
  103. AC Musta, 2009, Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years, Journal of clinical microbiology, 47, 1640, 10.1128/JCM.02135-08 · DOI
  104. SM Tallent, 2002, Vancomycin Susceptibility of Oxacillin-Resistant Staphylococcus aureus Isolates Causing Nosocomial Bloodstream Infections, Journal of clinical microbiology, 40, 2249, 10.1128/JCM.40.6.2249-2250.2002 · DOI
  105. AM Pitz, 2011, Vancomycin susceptibility trends and prevalence of heterogeneous vancomycin-intermediate Staphylococcus aureus in clinical methicillin-resistant S. aureus isolates, Journal of clinical microbiology, 49, 269, 10.1128/JCM.00914-10 · DOI
  106. MN Kim, 2000, Vancomycin-intermediate Staphylococcus aureus in Korea, Journal of clinical microbiology, 38, 3879, 10.1128/JCM.38.10.3879-3881.2000 · DOI
  107. M Pastagia, 2012, Predicting risk for death from MRSA bacteremia, Emerging Infectious Diseases, 18, 1072, 10.3201/eid1807.101371 · DOI
  108. G CG, 2004, Glycopeptide resistance in Staphylococcus aureus: is it a real threat?, Journal of infection and chemotherapy: official journal of the Japan Society of Chemotherapy, 10, 69, 10.1007/s10156-004-0307-5 · DOI
  109. Y T, 2011, Clinical characteristics of vancomycin minimum inhibitory concentration of 2 μg/ml methicillin-resistant Staphylococcus aureus strains isolated from patients with bacteremia, Journal of Infection and Chemotherapy, 17, 52, 10.1007/s10156-010-0086-0 · DOI
  110. CL Moore, 2012, Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study, Clin Infect Dis, 54, 51, 10.1093/cid/cir764 · DOI · Paper page
  111. FC Tenover, 2001, Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus, Emerg Infect Dis, 7, 327, 10.3201/eid0702.010237 · DOI · Paper page
  112. M Saito, 2014, "Slow VISA," a novel phenotype of vancomycin resistance, found in vitro in heterogeneous vancomycin-intermediate Staphylococcus aureus strain Mu3, Antimicrobial agents and chemotherapy, 58, 5024, 10.1128/AAC.02470-13 · doi:10.1128/aac.02470-13
  113. PL Ho, 2010, Vancomycin MIC creep in MRSA isolates from 1997 to 2008 in a healthcare region in Hong Kong, The Journal of infection, 60, 140, 10.1016/j.jinf.2009.11.011 · doi:10.1016/j.jinf.2009.11.011
  114. W Chang, 2015, Vancomycin MIC creep in methicillin-resistant Staphylococcus aureus (MRSA) isolates from 2006 to 2010 in a hospital in China, Indian journal of medical microbiology, 33, 262, 10.4103/0255-0857.148837 · DOI
  115. CJ Chen, 2014, New epidemiology of Staphylococcus aureus infection in Asia, Clin Microbiol Infect, 20, 605, 10.1111/1469-0691.12705 · DOI · Paper page
  116. Y K, 2000, A new class of genetic element, staphylococcus cassette chromosome mec, encodes methicillin resistance in Staphylococcus aureus, Antimicrobial agents and chemotherapy, 44, 1549, 10.1128/AAC.44.6.1549-1555.2000 · DOI · Paper page
  117. TS N, 2003, Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection, JAMA, 290, 2976, 10.1001/jama.290.22.2976 · DOI · Paper page
  118. SL K, 2006, In vitro exposure of community-associated methicillin-resistant Staphylococcus aureus (MRSA) strains to vancomycin: does vancomycin resistance occur?, International journal of antimicrobial agents, 27, 168, 10.1016/j.ijantimicag.2005.10.009 · DOI
  119. J E, 2013, Carriage frequency, diversity and methicillin resistance of Staphylococcus aureus in Danish small ruminants, Veterinary Microbiology, 163, 110, 10.1016/j.vetmic.2012.12.006 · DOI
  120. M Aires de Sousa, 2005, Comparison of genetic backgrounds of methicillin-resistant and -susceptible Staphylococcus aureus isolates from Portuguese hospitals and the community, Journal of clinical microbiology, 43, 5150, 10.1128/JCM.43.10.5150-5157.2005 · DOI
  121. M L, 2012, MRSA epidemic linked to a quickly spreading colonization and virulence determinant, Nature Medicine, 18, 816, 10.1038/nm.2692 · DOI · Paper page

Cited by

See all 99

Metadata

Authors
Zhang, S., Sun, X., Chang, W., Dai, Y., & Ma, X.
Venue
PLOS ONE
Published
2015-08-19
Volume
10
Issue
8
Pages
e0136082
ISSN
1932-6203
Cited by
99
References
3
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Systematic Review and Meta-Analysis of the Epidemiology of Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Isolates. https://app.cochat.ai/papers/10.1371/journal.pone.0136082
The paper
Zhang, S., Sun, X., Chang, W., Dai, Y., & Ma, X. (2015). Systematic Review and Meta-Analysis of the Epidemiology of Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Isolates. PLOS ONE. https://doi.org/10.1371/journal.pone.0136082

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.